Pro Medicus shares (ASX: PME) jumped 4.94% on Tuesday to close at A$172.82, delivering the kind of bounce that has become increasingly rare for the medical imaging software group over recent months. The PME share price had pulled back to test the A$160 support level in recent days, following what has been a particularly volatile couple of months for holders.
From the start of June into July 6th, Pro Medicus’ share price rallied 61%, before taking a 24% pullback ahead of last weekend. Whipsaw price action that resembles a rollercoaster on the chart is not for everyone.
Digging a little deeper, the broader technical picture remains under pressure, with the share price still trading below its 50-day moving average and that shorter-term gauge itself sitting beneath the 200-day line.
Pro Medicus has been caught in a valuation reset since earlier this year, with investors questioning whether the premium multiple that once seemed justified by the company’s track record of large hospital contract wins can hold in a market that has become more cautious on long-duration growth stocks. The February 2026 half-year result, which showed continued strong performance, remains the most recent confirmed corporate milestone, but it has not been enough to arrest the technical drift. The shares have been digesting prior selling pressure, and while today’s gain is notable, it does not yet negate the broader downtrend structure, with the stock down 22.37% YTD.
The technical setup remains bearish in the medium term. The 50-day moving average sits at 173.97, just above the current price, while the 200-day line is higher still at 180.49. That negative alignment is a textbook sign of weakened momentum, and although the ADX reading of 34.52 confirms that trend strength is present, the indicator is falling, suggesting that the selling pressure may be losing steam rather than accelerating. For bulls, that fading momentum could open the door to a more sustained recovery, but only if the stock can reclaim the 50-day average and hold it convincingly.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
View From The Street
Analyst consensus remains mildly constructive, with a target price of A$190.54 implying upside of around 10.6% from current levels. The valuation debate is central to understanding Pro Medicus’s recent performance.
The company has built a strong reputation for winning large, multi-year contracts with major hospital systems, and its cloud-based imaging platform has delivered consistent growth. But high-quality growth stories are not immune to multiple compression, particularly when the market shifts its focus from long-term potential to near-term earnings visibility. The stock’s premium rating, once a badge of honour, has become a vulnerability as investors rotate toward cheaper cyclicals or more defensive positions.
The latest bounce off A$160 is a start, but the technical and sentiment challenges remain. Bulls will be watching for a sustained move above the 50-day average, ideally on stronger volume, to confirm that the worst is over. Bears, meanwhile, will point to the negative moving-average alignment and the modest upside implied by consensus targets as evidence that the risk-reward remains skewed to the downside. The next few sessions will be telling.
Bull Case:
- Consensus target 10.6% above current price suggests Street sees value
- Falling ADX hints selling pressure may be exhausting
- Low beta limits downside risk from broader market volatility
Bear Case:
- Price remains below 50-day and 200-day moving averages
- No fresh catalyst to justify sustained reversal
- Premium valuation vulnerable if growth expectations moderate
